Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.28 | N/A | -16.26% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.28 | N/A | -16.26% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current market conditions. They highlighted ongoing efforts to address operational challenges.
Management did not provide specific revenue figures for the quarter.
The company acknowledged challenges in meeting earnings expectations.
Biocryst Pharmaceuticals reported a wider-than-expected loss in EPS, which contributed to a 2.02% decline in stock price following the announcement. The lack of revenue figures and guidance may raise concerns among investors about the company's future performance. Overall, the report reflects ongoing challenges that could impact investor confidence.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
OCCIDENTAL PETE CORP
Nov 5, 2018